Concord Biotech Limited Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Concord Biotech Limited's estimated annual revenue is currently $164.5M per year.(i)
  • Concord Biotech Limited's estimated revenue per employee is $155,000

Employee Data

  • Concord Biotech Limited has 1061 Employees.(i)
  • Concord Biotech Limited grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Concord Biotech Limited?

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API's and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing. The existing portfolio of products includes API's in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

keywords:N/A

N/A

Total Funding

1061

Number of Employees

$164.5M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Concord Biotech Limited News

2022-04-17 - Hemolytic anemia Market Size, Share,Trends Analysis, Top ...

... Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy's Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited,...

2022-04-06 - Adiso Therapeutics Announces Completion of First Cohort Enrollment in a Phase 1b Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

CONCORD, Mass., April 13, 2022 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines...

2022-04-06 - Rakesh Jhunjhunwala sells stake in Escorts, stock price falls

... Focus Limited, Geojit Financial Services, Bilcare Limited, Praj Industries Limited, Provogue India Limited, Concord Biotech Limited,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$237.2M12107%N/A
#2
$278.2M12381%N/A
#3
$127.1M125212%N/A
#4
$115.4M12688%N/A
#5
$129.8M1279-1%N/A